TQB2922 + TAS-102 + bevacizumab

This is a **combination regimen** consisting of three agents: TQB2922, TAS-102, and bevacizumab. - **TQB2922** is a novel antineoplastic agent developed by Chia Tai Tianqing Pharmaceutical Group and Nanjing Shunxin Pharmaceutical. Its precise mechanism of action is currently **undefined** in public sources, but it is under development for the treatment of advanced cancers, including colorectal cancer[5][3][7][9]. - **TAS-102** (trifluridine/tipiracil) is an oral nucleoside antitumor agent that incorporates trifluridine, a thymidine-based cytotoxic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor that increases trifluridine bioavailability. TAS-102 exerts its effect by interfering with DNA synthesis and function in cancer cells. - **Bevacizumab** is a recombinant humanized monoclonal antibody that binds **vascular endothelial growth factor A (VEGF-A)**, inhibiting angiogenesis (the formation of new blood vessels) essential for tumor growth. It is widely used for metastatic colorectal cancer and multiple other solid malignancies[2][4][6][8][10]. The combination is under clinical investigation for the treatment of **advanced colorectal cancer** in patients with RAS/BRAF wild-type tumors who have failed prior therapies[1].

Other names

TQB-2922TQB2922TQB 2922trifluridine/tipiracilbevacizumab